Medtronic Upbeat On Drug-Eluting Stents In Patients With DAPT
Zacks Investment Research | Oct 01, 2019 09:23PM ET
Medtronic plc (NYSE:MDT) has announced the release of clinical data from the Onyx ONE Global Study. The company claims this to be the first potential, multi-center, randomized study, assessing clinical results between two drug-eluting stents (“DES”) in approximately 2,000 high-bleeding risk (“HBR”) patients with one month of dual antiplatelet therapy (“DAPT”).
Results of the study were presented at the clinical trial session at the 31st Transcatheter Cardiovascular Therapeutics (TCT) (the annual scientific symposium of the Cardiovascular Research Foundation) in San Francisco.
With the publication of the study, Medtronic aims to fortify its position in the global peripheral vascular devices market.
The Study in Detail
The main objective of the study was to fulfill the primary composite endpoint of proving that it is no way inferior to the comparator stent, BioFreedom DCS, with respect to cardiac death, myocardial infarction (MI) or stent thrombosis (ST) at one-year. Along with this, the study confirmed better performance of Resolute Onyx, with shortened DAPT.
Per Medtronic, BioFreedom DCS is the only DES mentioned by the European Society for Cardiology (ESC) in its guidelines for HBR patients, who may need one-month DAPT.
The results obtained from the study, with respect to target lesion revascularization (“TLR”) and ST, were quite impressive for Resolute Onyx compared with BioFreedom.
Significance of the Study
Per the medical fraternity participating in the study, with the increasing number of patients with HBR, who make up almost 40% of percutaneous coronary intervention (PCI) patients, it was crucial to generate randomized clinical evidence to assess results for these patients. The positive outcome of the study will likely aid physicians to shorten the duration of DAPT, following PCI among HBR patients.
The most important outcome of this study is obtaining low event rates for Resolute Onyx after the discontinuation of DAPT at one month. The composite endpoint (cardiac death, ST, MI) of the study was quite spectacular.
Industry Prospects
Per a report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.